CATX vs FHTX
CATX: Perspective Therapeutics is a clinical-stage oncology company pioneering targeted alpha therapy (TAT) to treat cancer through a proprietary radiopharmaceutical platform. FHTX: Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal gene expression.
Side-by-side fundamentals
| Metric | CATX | FHTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.97 | $5.21 | |
| Market cap as of 2026-07-23 | $337M | $306M | |
| PEG as of 2026-07-23 | -0.14 | n/a | |
| Net margin as of 2026-07-23 | -17982.7% | -266.9% | FHTX higher |
| Gross margin as of 2026-07-23 | +23.0% | n/a | |
| Operating margin as of 2026-07-23 | -19419.6% | -301.3% | FHTX higher |
| ROE as of 2026-07-23 | -41.8% | -301.6% | CATX higher |
| ROA as of 2026-07-23 | -34.6% | -35.4% | CATX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | FHTX lower |
| Revenue growth (YoY) as of 2026-07-23 | -58.0% | +20.1% | FHTX higher |
| Revenue CAGR (3y) SEC XBRL | +11.4% | +17.1% | FHTX higher |
| Beta as of 2026-07-23 | 1.76 | 2.80 | |
| 1-year return as of 2026-07-22 close | -30.9% | -15.4% | FHTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.